Reportable Segment Information

12 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Reportable Segment Information

13. Reportable Segment Information

Reportable segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments:

•Medical Device: Manufacture of performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular, and structural heart, among others; and the manufacture of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.

•In Vitro Diagnostics: Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Component products include protein stabilizers, substrates, surface coatings and antigens.

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2022			2021			2020
Revenue:
Medical Device	$	72,389		$	78,253		$	71,401
In Vitro Diagnostics		27,562			26,883			23,463
Total revenue	$	99,951		$	105,136		$	94,864
Operating (loss) income:
Medical Device	$	(22,923	)	$	4,683		$	(3,246	)
In Vitro Diagnostics		13,073			13,770			11,771
Total segment operating (loss) income		(9,850	)		18,453			8,525
Corporate		(12,247	)		(11,750	)		(9,776	)
Total operating (loss) income	$	(22,097	)	$	6,703		$	(1,251	)
Depreciation and amortization:
Medical Device	$	8,368		$	7,224		$	6,223
In Vitro Diagnostics		355			395			483
Corporate		419			398			557
Total depreciation and amortization	$	9,142		$	8,017		$	7,263

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Revenue by geographic region was as follows:

	Fiscal Year
	2022			2021			2020
Domestic		74	%		79	%		78	%
Foreign		26	%		21	%		22	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2022		2021
U.S.	$	24,788	$	25,920
Ireland		30,505		41,224